Access
This article is part of Nature's premium content.
Published online 9 July 2008 | Nature | doi:10.1038/454144a
When there's no room to grow
To maintain profits in the face of rising development costs and slow drug pipelines, big pharmaceutical firms are trying to cut back. Heidi Ledford examines how GlaxoSmithKline has tried to adapt.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
